NEW YORK (TheStreet) --  MSCI's move to exclude China's A-listed shares from its well-known Emerging Markets Index is making one strategist cautious.

"We're a little concerned about the parabolic move we've seen in the A-Share market," said Mark Luschini, chief investment strategist at Janney Montgomery Scott. "But the H-Shares, which are Chinese-domiciled companies traded and listed in Hong Kong, are selling at a 25% discount to their A-Share counterparts, so there's much better valuation there."

He said Chinese stocks have been bid up due to anticipation that they would be included in the index, and also based on stimulus from the People's Bank of China, which is why he suggests being 'long, but cautious.'

Luschini said MSCI's decision was largely due to the immaturity of the Chinese market. "It's notorious that stocks listed in China are subject to a lot of retail buying and selling -- a lot of speculation, if not outright manipulation," he said.

The iShares MSCI Emerging Markets ETF has returned about 2% since the start of the year.

Stocks in China didn't react well to the news. The Shanghai Composite closed Wednesday's trading day at 5106.04, down 0.15%, after reaching an intraday high of 5162.79.

He said investors who have not yet made a commitment to investing in China should wait until the Chinese central bank's stimulus efforts have done more to improve economic conditions.

"We need to see the stimulus measures from the People's Bank of China actually start to work in the economy and right now there isn't clear evidence that's occurring," he said.

Meanwhile, Luschini's summer strategy centers around the financials sector. "With the slight uptick we've had in interest rates recently, there's opportunity for the banks' net interest margin to expand."

Yields on the benchmark 10-year Treasury stand at 2.46%, compared to 2.12% at the beginning of the year.

Financial stocks in the S&P 500 have fallen 0.4% since the start of the year, and include names like Bank of America (BAC), JPMorgan Chase (JPM) and Wells Fargo (WFC).

Luschini is also bullish on Gilead Sciences (GILD).

"It's trading at 10 times earnings, so you have good valuations, compared to the market and the health care sector," he said.

This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.

If you liked this article you might like

Where's My Toaster? Banks Want Your Business

Where's My Toaster? Banks Want Your Business

24 Stocks Hedge Funds Are Loving Right Now

24 Stocks Hedge Funds Are Loving Right Now

It's Dumb to Think Amazon Will Be Able to Skirt Regulators Forever

It's Dumb to Think Amazon Will Be Able to Skirt Regulators Forever

Citigroup Gives CEO Corbat 48% Pay Raise as Profitability Misses Goal

Citigroup Gives CEO Corbat 48% Pay Raise as Profitability Misses Goal

Worst-In-Class Goldman Sachs CEO Blankfein Gets 9% Pay Raise

Worst-In-Class Goldman Sachs CEO Blankfein Gets 9% Pay Raise